Tivozanib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 190 publications

Drug-Drug Interactions as a Challenge in the Monotherapy of Advanced or Metastatic Clear-Cell Renal Cell Carcinoma with VEGFR-Associated Tyrosine Kinase Inhibitors

Drug-Drug Interactions as a Challenge in the Monotherapy of Advanced or Metastatic Clear-Cell Renal Cell Carcinoma with VEGFR-Associated Tyrosine Kinase Inhibitors

Journal: Aktuelle Urologie
Published: February 05, 2026

Mechanistic insights into Gwt1-substrate interactions and antifungal drug discovery via molecular dynamics and virtual screening.

Mechanistic insights into Gwt1-substrate interactions and antifungal drug discovery via molecular dynamics and virtual screening.

Journal: Journal of biomolecular structure & dynamics
Published: January 12, 2026

A Systematic Review Comparing Sex-Specific Outcomes of Prospective Clinical Trials and Subsequent Real-World Data Focusing on Systemic Treatment Options for Renal Cell Cancer.

A Systematic Review Comparing Sex-Specific Outcomes of Prospective Clinical Trials and Subsequent Real-World Data Focusing on Systemic Treatment Options for Renal Cell Cancer.

Journal: Urologia internationalis
Published: December 03, 2025

Sitagliptin does not interfere with VEGF-A signaling in retinal endothelial cells in vitro.

Sitagliptin does not interfere with VEGF-A signaling in retinal endothelial cells in vitro.

Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
Published: November 25, 2025

First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

Journal: Cancers
Published: October 16, 2025

Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: a network meta-analysis.

Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: a network meta-analysis.

Journal: BMC cancer
Published: October 10, 2025

Vascular endothelial cells and angiogenesis.

Vascular endothelial cells and angiogenesis.

Journal: Pharmacological research
Published: October 04, 2025

2-Chloro-4-hy-droxy-anilinium chloride.

2-Chloro-4-hy-droxy-anilinium chloride.

Journal: IUCrData
Published: October 02, 2025

From Biomarker to Drug Target: Integrating ceRNA Networks and Pharmacogenomics to Reposition C5orf34 in Uterine Corpus Endometrial Cancer Therapy.

From Biomarker to Drug Target: Integrating ceRNA Networks and Pharmacogenomics to Reposition C5orf34 in Uterine Corpus Endometrial Cancer Therapy.

Journal: Current medicinal chemistry
Published: September 02, 2025

Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis.

Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis.

Journal: Tumori
Published: August 29, 2025

Buccodental Toxicities Induced by Tyrosine Kinase Inhibitors in Patients Diagnosed with Renal Cell Carcinoma-A Literature Review.

Buccodental Toxicities Induced by Tyrosine Kinase Inhibitors in Patients Diagnosed with Renal Cell Carcinoma-A Literature Review.

Journal: Dentistry journal
Published: August 11, 2025

Association of HTR1F with Prognosis, Tumor Immune Microenvironment, and Drug Sensitivity in Cancer: A Multi-Omics Perspective.

Association of HTR1F with Prognosis, Tumor Immune Microenvironment, and Drug Sensitivity in Cancer: A Multi-Omics Perspective.

Journal: Biomedicines
Published: July 17, 2025
Showing 1-12 of 190

Last Updated: 06/30/2026